1
|
An overview of kinin mediated events in cancer progression and therapeutic applications. Biochim Biophys Acta Rev Cancer 2022; 1877:188807. [PMID: 36167271 DOI: 10.1016/j.bbcan.2022.188807] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 09/12/2022] [Accepted: 09/21/2022] [Indexed: 11/22/2022]
Abstract
Kinins are bioactive peptides generated in the inflammatory milieu of the tissue microenvironment, which is involved in cancer progression and inflammatory response. Kinins signals through activation of two G-protein coupled receptors; inducible Bradykinin Receptor B1 (B1R) and constitutive receptor B2 (B2R). Activation of kinin receptors and its cross-talk with receptor tyrosine kinases activates multiple signaling pathways, including ERK/MAPK, PI3K, PKC, and p38 pathways regulating cancer hallmarks. Perturbations of the kinin-mediated events are implicated in various aspects of cancer invasion, matrix remodeling, and metastasis. In the tumor microenvironment, kinins initiate fibroblast activation, mesenchymal stem cell interactions, and recruitment of immune cells. Albeit the precise nature of kinin function in the metastasis and tumor microenvironment are not completely clear yet, several kinin receptor antagonists show anti-metastatic potential. Here, we showcase an overview of the complex biology of kinins and their role in cancer pathogenesis and therapeutic aspects.
Collapse
|
2
|
Liotti F, Marotta M, Melillo RM, Prevete N. The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression. Cancers (Basel) 2022; 14:3333. [PMID: 35884394 PMCID: PMC9316558 DOI: 10.3390/cancers14143333] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 07/06/2022] [Accepted: 07/07/2022] [Indexed: 12/23/2022] Open
Abstract
Non-resolving inflammation is an enabling feature of cancer. A novel super-family of lipid mediators termed Specialized Pro-resolving Mediators (SPMs) have a role as bioactive molecules mediating the resolution of inflammation in cancer biology. SPMs are derived from ω-3 and ω-6 polyunsaturated fatty acids through the activity of lipoxygenases. SPMs have been described to directly modulate cancer progression by interfering with the epithelial to mesenchymal transition and invasion of cancer cells. SPMs have also been demonstrated to act on several components of the tumor microenvironment (TME). Consistently with their natural immunomodulatory and anti-inflammatory properties, SPMs are able to reprogram macrophages to favor phagocytosis of cell debris, which are an important source of pro-inflammatory and pro-angiogenic signals; sustain a direct cytotoxic immune response against cancer cells; stimulate neutrophils anti-tumor activities; and inhibit the development of regulatory T and B cells, thus indirectly leading to enhanced anti-tumor immunity. Furthermore, the resolution pathways exert crucial anti-angiogenic functions in lung, liver, and gastrointestinal cancers, and inhibit cancer-associated fibroblast differentiation and functions in hepatocellular carcinoma and pancreatic cancer. The present review will be focused on the potential protective effects of resolution pathways against cancer, exerted by modulating different components of the TME.
Collapse
Affiliation(s)
- Federica Liotti
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy; (F.L.); (M.M.)
- Institute of Experimental Endocrinology and Oncology (IEOS), CNR, 80131 Naples, Italy
| | - Maria Marotta
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy; (F.L.); (M.M.)
| | - Rosa Marina Melillo
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy; (F.L.); (M.M.)
- Institute of Experimental Endocrinology and Oncology (IEOS), CNR, 80131 Naples, Italy
| | - Nella Prevete
- Institute of Experimental Endocrinology and Oncology (IEOS), CNR, 80131 Naples, Italy
- Department of Translational Medical Sciences, University of Naples Federico II, 80131 Naples, Italy
| |
Collapse
|
3
|
Abstract
Coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an ongoing pandemic causing significant morbidity and mortality worldwide. The “cytokine storm” is a critical driving force in severe COVID-19 cases, leading to hyperinflammation, multi-system organ failure, and death. A paradigm shift is emerging in our understanding of the resolution of inflammation from a passive course to an active biochemical process driven by endogenous specialized pro-resolving mediators (SPMs), such as resolvins, protectins, lipoxins, and maresins. SPMs stimulate macrophage-mediated debris clearance and counter pro-inflammatory cytokine production, a process collectively termed as the “resolution of inflammation.” Hyperinflammation is not unique to COVID-19 and also occurs in neoplastic conditions, putting individuals with underlying health conditions such as cancer at elevated risk of severe SARS-CoV-2 infection. Despite approaches to block systemic inflammation, there are no current therapies designed to stimulate the resolution of inflammation in patients with COVID-19 or cancer. A non-immunosuppressive therapeutic approach that reduces the cytokine storm in patients with COVID-19 and cancer is urgently needed. SPMs are potent immunoresolvent and organ-protective lipid autacoids that stimulate the resolution of inflammation, facilitate clearance of infections, reduce thrombus burden, and promote a return to tissue homeostasis. Targeting endogenous lipid mediators, such as SPMs, offers an entirely novel approach to control SARS-CoV-2 infection and cancer by increasing the body’s natural reserve of pro-resolving mediators without overt toxicity or immunosuppression.
Collapse
Affiliation(s)
- Chantal Barksdale
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA
| | - Franciele C Kipper
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA
| | - Shreya Tripathy
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA
| | - Selvakumar Subbian
- Public Health Research Institute, New Jersey Medical School, Rutgers University, Newark, NJ, 07103, USA
| | - Charles N Serhan
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02215, USA
| | - Dipak Panigrahy
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. .,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. .,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.
| |
Collapse
|
4
|
Beyond immune checkpoint blockade: emerging immunological strategies. Nat Rev Drug Discov 2021; 20:899-919. [PMID: 33686237 DOI: 10.1038/s41573-021-00155-y] [Citation(s) in RCA: 207] [Impact Index Per Article: 69.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/28/2021] [Indexed: 02/07/2023]
Abstract
The success of checkpoint inhibitors has accelerated the clinical implementation of a vast mosaic of single agents and combination immunotherapies. However, the lack of clinical translation for a number of immunotherapies as monotherapies or in combination with checkpoint inhibitors has clarified that new strategies must be employed to advance the field. The next chapter of immunotherapy should examine the immuno-oncology therapeutic failures, and consider the complexity of immune cell-cancer cell interactions to better design more effective anticancer drugs. Herein, we briefly review the history of immunotherapy and checkpoint blockade, highlighting important clinical failures. We discuss the critical aspects - beyond T cell co-receptors - of immune processes within the tumour microenvironment (TME) that may serve as avenues along which new therapeutic strategies in immuno-oncology can be forged. Emerging insights into tumour biology suggest that successful future therapeutics will focus on two key factors: rescuing T cell homing and dysfunction in the TME, and reappropriating mononuclear phagocyte function for TME inflammatory remodelling. New drugs will need to consider the complex cell networks that exist within tumours and among cancer types.
Collapse
|
5
|
Abstract
Cancer therapy, such as chemotherapy, induces tumor cell death (“debris”), which can stimulate metastasis. Chemotherapy-generated debris upregulates soluble epoxide hydrolase (sEH) and the prostaglandin E2 receptor 4 (EP4), which triggers a macrophage-derived storm of proinflammatory and proangiogenic lipid autacoid and cytokine mediators. Although sEH inhibitors and EP4 antagonists are in clinical development for multiple inflammatory diseases, their combined role in cancer is unknown. Here, we show that the synergistic antitumor activity of sEH and EP4 inhibition suppresses hepato-pancreatic tumor growth, without overt toxicity, via macrophage phagocytosis of debris and counterregulation of a debris-stimulated cytokine storm. Thus, stimulating the resolution of inflammation via combined inhibition of sEH and EP4 may be an approach for preventing metastatic progression driven by cancer therapy. Cancer therapy reduces tumor burden via tumor cell death (“debris”), which can accelerate tumor progression via the failure of inflammation resolution. Thus, there is an urgent need to develop treatment modalities that stimulate the clearance or resolution of inflammation-associated debris. Here, we demonstrate that chemotherapy-generated debris stimulates metastasis by up-regulating soluble epoxide hydrolase (sEH) and the prostaglandin E2 receptor 4 (EP4). Therapy-induced tumor cell debris triggers a storm of proinflammatory and proangiogenic eicosanoid-driven cytokines. Thus, targeting a single eicosanoid or cytokine is unlikely to prevent chemotherapy-induced metastasis. Pharmacological abrogation of both sEH and EP4 eicosanoid pathways prevents hepato-pancreatic tumor growth and liver metastasis by promoting macrophage phagocytosis of debris and counterregulating a protumorigenic eicosanoid and cytokine storm. Therefore, stimulating the clearance of tumor cell debris via combined sEH and EP4 inhibition is an approach to prevent debris-stimulated metastasis and tumor growth.
Collapse
|
6
|
Patel DN, Yeagley M, Arturo JF, Falasiri S, Chobrutskiy BI, Gozlan EC, Blanck G. A comparison of immune receptor recombination databases sourced from tumour exome or RNAseq files: Verifications of immunological distinctions between primary and metastatic melanoma. Int J Immunogenet 2021; 48:409-418. [PMID: 34298587 DOI: 10.1111/iji.12550] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 07/11/2021] [Indexed: 02/07/2023]
Abstract
It became apparent several years ago that RNAseq and exome files prepared from tissue could be mined for adaptive immune receptor (IR) recombinations, which has given extra value to datasets originally intended for gene expression or mutation studies. For example, recovery of IR recombination reads from tumour specimen genomics files can correlate with survival rates. In particular, many benchmarking processes have been applied to the two sets of the IR recombination reads obtained from the cancer genome atlas files, but these two sets have never been directly compared. Here we show that both sets largely agree regarding several parameters. For example, recovery of TRB recombination reads from both WXS and RNAseq files representing metastatic melanoma was associated with a better outcome (p < .0004 in both cases); and T-cell receptor recombination read recovery, for both genomics file types, associated very strongly with T-cell gene expression markers. However, the use of CDR3 chemical features for survival distinctions was not consistent. This topic, and the surprising result that both datasets indicated that primary melanoma with recovery of IR recombination reads, in stark contrast to metastatic melanoma, represents a worse outcome, are discussed.
Collapse
Affiliation(s)
- Dhruv N Patel
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | - Michelle Yeagley
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | - Juan F Arturo
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | - Shayan Falasiri
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | - Boris I Chobrutskiy
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | - Etienne C Gozlan
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
| | - George Blanck
- Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.,Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| |
Collapse
|
7
|
Dos Santos CMM, Diniz VLS, Bachi ALL, Dos Santos de Oliveira LC, Ghazal T, Passos MEP, de Oliveira HH, Murata G, Masi LN, Martins AR, Levada-Pires AC, Curi R, Hirabara SM, Sellitti DF, Pithon-Curi TC, Gorjão R. Moderate physical exercise improves lymphocyte function in melanoma-bearing mice on a high-fat diet. Nutr Metab (Lond) 2019; 16:63. [PMID: 31528182 PMCID: PMC6739998 DOI: 10.1186/s12986-019-0394-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 09/06/2019] [Indexed: 02/16/2023] Open
Abstract
Background Obesity can lead to a chronic systemic inflammatory state that increases the risk of cancer development. Therefore, this study aimed to evaluate the alterations in tumor non-infiltrated lymphocytes function and melanoma growth in animals maintained on a high-fat diet and/or moderate physical exercise program in a murine model of melanoma. Methods Female mice were randomly divided into eight groups: 1) normolipidic control (N), 2) normolipidic + melanoma (NM), 3) high-fat control (H), 4) high-fat + melanoma (HM), 5) normolipidic control + physical exercise (NE), 6) normolipidic melanoma + physical exercise (NEM), 7) high-fat control + physical exercise (HE), and 8) high-fat melanoma + physical exercise (HEM). After 8 weeks of diet treatment and/or moderate physical exercise protocol, melanoma was initiated by explanting B16F10 cells into one-half of the animals. Results Animals fed a high-fat diet presented high-energy consumption (30%) and body weight gain (H and HE vs N and NE, 37%; HM and HEM vs NM and NEM, 73%, respectively), whether or not they carried melanoma explants. Although the tumor growth rate was higher in animals from the HM group than in animals from any other sedentary group, it was reduced by the addition of a physical exercise regimen. We also observed an increase in stimulated peripheral lymphocyte proliferation and a decrease in the T-helper 1 response in the HEM group. Conclusions The results of the present study support the hypothesis that altering function of tumor non-infiltrated lymphocytes via exercise-related mechanisms can slow melanoma progression, indicating that the incorporation of a regular practice of moderate-intensity exercises can be a potential strategy for current therapeutic regimens in treating advanced melanoma.
Collapse
Affiliation(s)
- Cesar Miguel Momesso Dos Santos
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Vinicius Leonardo Sousa Diniz
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - André Luis Lacerda Bachi
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil.,2Department of Otorrhynolaringology, Federal University of São Paulo, São Paulo, Brazil.,Brazilian Institute of Teaching and Research in Pulmonary and Exercise Immunology (IBEPIPE), São Paulo, Brazil
| | - Laiane Cristina Dos Santos de Oliveira
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Tamara Ghazal
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Maria Elizabeth Pereira Passos
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Heloisa Helena de Oliveira
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Gilson Murata
- 4Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1374, CEP: 05508-900, Butanta, São Paulo, Brazil
| | - Laureane Nunes Masi
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Amanda Roque Martins
- 4Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1374, CEP: 05508-900, Butanta, São Paulo, Brazil
| | - Adriana Cristina Levada-Pires
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Rui Curi
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Sandro Massao Hirabara
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Donald F Sellitti
- 5Department of Medicine, Uniformed Services University of Health Sciences, 4301 Jones Bridge Road, Bethesda, MD USA
| | - Tania Cristina Pithon-Curi
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| | - Renata Gorjão
- 1Interdisciplinary Post-graduate Program in Health Sciences, Cruzeiro do Sul University, Rua Galvão Bueno, 868, CEP: 01506 000, Liberdade, São Paulo, Brazil
| |
Collapse
|
8
|
A Mixture of Polyunsaturated Fatty Acids ω-3 and ω-6 Reduces Melanoma Growth by Inhibiting Inflammatory Mediators in the Murine Tumor Microenvironment. Int J Mol Sci 2019; 20:ijms20153765. [PMID: 31374840 PMCID: PMC6695743 DOI: 10.3390/ijms20153765] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Revised: 07/26/2019] [Accepted: 07/29/2019] [Indexed: 02/06/2023] Open
Abstract
Background: Although it has been previously demonstrated that acute inflammation can promote the tumor growth of a sub-tumorigenic dose of melanoma cells through of 5-lipoxygenase inflammatory pathway and its product leukotriene B4, and also that the peritumoral treatment with eicosapentaenoic acid and its product, leukotriene B5, reduces the tumor development, the effect of the treatment by gavage with omega-3 and omega-6 in the tumor microenvironment favorable to melanoma growth associated with acute inflammation has never been studied. Methods: C57BL/6 mice were coinjected with 1 × 106 apoptotic cells plus 1 × 103 viable melanoma cells into the subcutaneous tissue and treated by gavage with omega-3-rich fish oil or omega-6-rich soybean oil or a mixture of these oils (1:1 ratio) during five consecutive days. Results: The treatment by gavage with a mixture of fish and soybean oils (1:1 ratio) both reduced the melanoma growth and the levels of leukotriene B4 (LTB4), prostaglandin E2 (PGE2), PGE2/prostaglandin E3 (PGE3) ratio, and CXC ligand 1 (CXCL1) and increased the levels of interleukin 10 (IL-10) to IL-10/CXCL1 ratio in the melanoma microenvironment. Conclusion: The oral administration of a 1:1 mixture of fish oil and soybean oil was able to alter the release of inflammatory mediators that are essential for a microenvironment favorable to the melanoma growth in mice, whereas fish oil or soybean oil alone was ineffective.
Collapse
|
9
|
Inflammatory response and biomechanical properties of coaxial scaffolds for engineered skin in vitro and post-grafting. Acta Biomater 2018; 80:247-257. [PMID: 30218778 DOI: 10.1016/j.actbio.2018.09.014] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Revised: 08/30/2018] [Accepted: 09/11/2018] [Indexed: 12/19/2022]
Abstract
Engineered skin (ES) offers many advantages over split-thickness skin autografts for the treatment of burn wounds. However, ES, both in vitro and after grafting, is often significantly weaker, less elastic and more compliant than normal human skin. Biomechanical properties of ES can be tuned in vitro using electrospun co-axial (CoA) scaffolds. To explore the potential for coaxial scaffold-based ES use in vivo, two CoA scaffolds were fabricated with bioactive gelatin shells and biodegradable synthetic cores of polylactic acid (PLA) and polycaprolactone (PCL), and compared with gelatin monofilament scaffolds. Fibroblast and macrophage production of inflammatory cytokines interleukin 6 (IL-6) and transforming growth factor β-1 was significantly higher when cultured on PLA and PCL monofilament scaffolds compared to gelatin monofilament scaffolds. The core-shell fiber configuration significantly reduced production of pro-inflammatory cytokines to levels similar to those of gelatin monofilament scaffolds. In vitro, ES mechanical properties were significantly enhanced using CoA scaffolds; however, after grafting CoA- and gelatin-based ES to full-thickness excisional wounds on athymic mice, the in vitro mechanical advantage of CoA grafts was lost. A substantially increased inflammatory response to CoA-based ES was observed, with upregulation of IL-6 expression and a significant M2 macrophage presence. Additionally, expression of matrix metalloproteinase I was upregulated and collagen type I alpha 1 was downregulated in CoA ES two weeks after grafting. These results suggest that while coaxial scaffolds provide the ability to regulate biomechanics in vitro, further investigation of the inflammatory response to core materials is required to optimize this strategy for clinical use. STATEMENT OF SIGNIFICANCE: Engineered skin has been used to treat very large burn injuries. Despite its ability to heal these wounds, engineered skin exhibits reduced biomechanical properties making it challenging to manufacture and surgically apply. Coaxial fiber scaffolds have been utilized to tune the mechanical properties of engineered skin while maintaining optimal biological properties but it is not known how these perform on a patient especially with regards to their inflammatory response. The current study examines the biomechanical and inflammatory properties of coaxial scaffolds and uniaxial scaffolds in vitro and in vivo. The results show that the biological response to the scaffold materials is a critical determinant of tissue properties after grafting with reduced inflammation and rapid scaffold remodeling leading to stronger skin.
Collapse
|
10
|
Chang J, Bhasin SS, Bielenberg DR, Sukhatme VP, Bhasin M, Huang S, Kieran MW, Panigrahy D. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. FASEB J 2018; 33:114-125. [PMID: 29957058 PMCID: PMC6355061 DOI: 10.1096/fj.201800019rr] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Colon cancer recurrence after therapy, such as 5-fluorouracil (5-FU), remains a challenge in the clinical setting. Chemotherapy reduces tumor burden by inducing cell death; however, the resulting dead tumor cells, or debris, may paradoxically stimulate angiogenesis, inflammation, and tumor growth. Here, we demonstrate that 5-FU–generated colon carcinoma debris stimulates the growth of a subthreshold inoculum of living tumor cells in subcutaneous and orthotopic models. Debris triggered the release of osteopontin (OPN) by tumor cells and host macrophages. Both coinjection of debris and systemic treatment with 5-FU increased plasma OPN levels in tumor-bearing mice. RNA expression levels of secreted phosphoprotein 1, the gene that encodes OPN, correlate with poor prognosis in patients with colorectal cancer and are elevated in chemotherapy-treated patients who experience tumor recurrence vs. no recurrence. Pharmacologic and genetic ablation of OPN inhibited debris-stimulated tumor growth. Systemic treatment with a combination of a neutralizing OPN antibody and 5-FU dramatically inhibited tumor growth. These results demonstrate a novel mechanism of tumor progression mediated by OPN released in response to chemotherapy-generated tumor cell debris. Neutralization of debris-stimulated OPN represents a potential therapeutic strategy to overcome the inherent limitation of cytotoxic therapies as a result of the generation of cell debris.—Chang, J., Bhasin, S. S., Bielenberg, D. R., Sukhatme, V. P., Bhasin, M., Huang, S., Kieran, M. W., Panigrahy, D. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin.
Collapse
Affiliation(s)
- Jaimie Chang
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Swati S Bhasin
- Division of Interdisciplinary Medicine and Biology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Diane R Bielenberg
- Vascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.,Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
| | - Vikas P Sukhatme
- Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Manoj Bhasin
- Division of Interdisciplinary Medicine and Biology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| | - Sui Huang
- Institute for Systems Biology, Seattle, Washington, USA
| | - Mark W Kieran
- Division of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.,Department of Pediatric Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Dipak Panigrahy
- Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.,Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
11
|
da Silva-Junior IA, Dalmaso B, Herbster S, Lepique AP, Jancar S. Platelet-Activating Factor Receptor Ligands Protect Tumor Cells from Radiation-Induced Cell Death. Front Oncol 2018; 8:10. [PMID: 29459885 PMCID: PMC5807395 DOI: 10.3389/fonc.2018.00010] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Accepted: 01/15/2018] [Indexed: 12/17/2022] Open
Abstract
Irradiation generates oxidized phospholipids that activate platelet-activating factor receptor (PAFR) associated with pro-tumorigenic effects. Here, we investigated the involvement of PAFR in tumor cell survival after irradiation. Cervical cancer samples presented higher levels of PAF-receptor gene (PTAFR) when compared with normal cervical tissue. In cervical cancer patients submitted to radiotherapy (RT), the expression of PTAFR was significantly increased. Cervical cancer-derived cell lines (C33, SiHa, and HeLa) and squamous carcinoma cell lines (SCC90 and SCC78) express higher levels of PAFR mRNA and protein than immortalized keratinocytes. Gamma radiation increased PAFR expression and induced PAFR ligands and prostaglandin E2 (PGE2) in these tumor cells. The blocking of PAFR with the antagonist CV3938 before irradiation inhibited PGE2 and increased tumor cells death. Similarly, human carcinoma cells transfected with PAFR (KBP) were more resistant to radiation compared to those lacking the receptor (KBM). PGE2 production by irradiated KBP cells was also inhibited by CV3988. These results show that irradiation of carcinoma cells generates PAFR ligands that protect tumor cells from death and suggests that the combination of RT with a PAFR antagonist could be a promising strategy for cancer treatment.
Collapse
Affiliation(s)
| | - Barbara Dalmaso
- Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
| | - Suellen Herbster
- Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
| | - Ana Paula Lepique
- Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
| | - Sonia Jancar
- Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
| |
Collapse
|
12
|
Xu Y, Jiang Y, Gai W, Yu B. Protective role of tenuigenin on sepsis-induced acute kidney injury in mice. Exp Ther Med 2017; 14:5051-5056. [PMID: 29201213 DOI: 10.3892/etm.2017.5164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Accepted: 03/03/2017] [Indexed: 12/19/2022] Open
Abstract
Acute kidney injury (AKI) is a severe complication of sepsis, which largely contributes to the associated high mortality rate. Tenuigenin (TNG) is a natural product isolated from Polygala tenuifolia root, which possesses anti-inflammatory and anti-oxidant properties. The present study investigated the effects of TNG on sepsis-associated AKI in mice subjected to cecal ligation and puncture (CLP). TNG was demonstrated to alleviate sepsis-induced AKI by reducing pathological changes and significantly decreasing the levels of blood urea nitrogen, serum creatinine and kidney coefficient. The production of inflammatory cytokines, including tumor necrosis factor α and interleukin-6, was markedly inhibited by TNG. Hematoxylin-eosin staining revealed that the morphological changes of kidney tissues in CLP mice were reversed following TNG treatment. Furthermore, treatment with TNG inhibited the production of nitric oxide and prostaglandin E2. Finally, TNG inhibited the activation of the nuclear factor-κB (NF-κB) signaling pathway. The present study suggested that TNG alleviates sepsis-induced AKI by inhibiting the NF-κB signaling pathway, which provides a novel approach for treating sepsis-induced AKI.
Collapse
Affiliation(s)
- Yan Xu
- Department of Urinary Surgery, Laiyang Central Hospital of Yantai, Yantai, Shandong 265200, P.R. China
| | - Yan Jiang
- Department of Burns and Plastic Surgery, Laiyang Central Hospital of Yantai, Yantai, Shandong 265200, P.R. China
| | - Wentao Gai
- Department of Urinary Surgery, Laiyang Central Hospital of Yantai, Yantai, Shandong 265200, P.R. China
| | - Botao Yu
- Department of Urinary Surgery, Laiyang Central Hospital of Yantai, Yantai, Shandong 265200, P.R. China
| |
Collapse
|
13
|
Lima L, Oliveira A, Campos L, Bonamino M, Chammas R, Werneck C, Vicente C, Barcinski M, Petersen L, Monteiro R. Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thromb Haemost 2017; 106:712-23. [DOI: 10.1160/th11-03-0143] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2011] [Accepted: 06/30/2011] [Indexed: 01/08/2023]
Abstract
SummaryShedding of microvesicles (MVs) by cancer cells is implicated in a variety of biological effects, including the establishment of cancer-associated hypercoagulable states. However, the mechanisms underlying malignant transformation and the acquisition of procoagulant properties by tumour-derived MVs are poorly understood. Here we investigated the procoagulant and prothrombotic properties of MVs produced by a melanocyte-derived cell line (melan-a) as compared to its tumourigenic melanoma counterpart Tm1. Tumour cells exhibit a two-fold higher rate of MVs production as compared to melan-a. Melanoma MVs display greater procoagulant activity and elevated levels of the clotting initiator protein tissue factor (TF). On the other hand, tumour- and melanocyte- derived MVs expose similar levels of the procoagulant lipid phosphatidylserine, displaying identical abilities to support thrombin generation by the prothrombinase complex. By using an arterial thrombosis model, we observed that melanoma- but not melanocyte-derived MVs strongly accelerate thrombus formation in a TF-dependent manner, and accumulate at the site of vascular injury. Analysis of plasma obtained from melanoma-bearing mice showed the presence of MVs with a similar procoagulant pattern as compared to Tm1 MVs produced in vitro. Remarkably, flow-cytometric analysis demonstrated that 60% of ex vivo MVs are TF-positive and carry the melanoma-associated antigen, demonstrating its tumour origin. Altogether our data suggest that malignant transformation in melanocytes increases the production of procoagulant MVs, which may contribute for a variety of coagulation- related protumoural responses.
Collapse
|
14
|
Chammas R, de Sousa Andrade LN, Jancar S. Oncogenic effects of PAFR ligands produced in tumours upon chemotherapy and radiotherapy. Nat Rev Cancer 2017; 17:253. [PMID: 28280268 DOI: 10.1038/nrc.2017.15] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Roger Chammas
- Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | | | - Sonia Jancar
- Instituto de Ciências Biomédicas da Universidade de São Paulo, São Paulo, Brazil
| |
Collapse
|
15
|
Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration. PLoS One 2016; 11:e0165371. [PMID: 27992423 PMCID: PMC5167550 DOI: 10.1371/journal.pone.0165371] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2016] [Accepted: 11/29/2016] [Indexed: 12/31/2022] Open
Abstract
Background The angiotensin-I converting enzyme (ACE) plays a central role in the renin-angiotensin system, acting by converting the hormone angiotensin-I to the active peptide angiotensin-II (Ang-II). More recently, ACE was shown to act as a receptor for Ang-II, and its expression level was demonstrated to be higher in melanoma cells compared to their normal counterparts. However, the function that ACE plays as an Ang-II receptor in melanoma cells has not been defined yet. Aim Therefore, our aim was to examine the role of ACE in tumor cell proliferation and migration. Results We found that upon binding to ACE, Ang-II internalizes with a faster onset compared to the binding of Ang-II to its classical AT1 receptor. We also found that the complex Ang-II/ACE translocates to the nucleus, through a clathrin-mediated process, triggering a transient nuclear Ca2+ signal. In silico studies revealed a possible interaction site between ACE and phospholipase C (PLC), and experimental results in CHO cells, demonstrated that the β3 isoform of PLC is the one involved in the Ca2+ signals induced by Ang-II/ACE interaction. Further studies in melanoma cells (TM-5) showed that Ang-II induced cell proliferation through ACE activation, an event that could be inhibited either by ACE inhibitor (Lisinopril) or by the silencing of ACE. In addition, we found that stimulation of ACE by Ang-II caused the melanoma cells to migrate, at least in part due to decreased vinculin expression, a focal adhesion structural protein. Conclusion ACE activation regulates melanoma cell proliferation and migration.
Collapse
|
16
|
Saito RDF, Tortelli TC, Jacomassi MD, Otake AH, Chammas R. Emerging targets for combination therapy in melanomas. FEBS Lett 2015; 589:3438-48. [PMID: 26450371 DOI: 10.1016/j.febslet.2015.09.022] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Revised: 09/25/2015] [Accepted: 09/25/2015] [Indexed: 12/21/2022]
Abstract
Cutaneous melanomas are often difficult to treat when diagnosed in advanced stages. Melanoma cells adapt to survive in extreme environmental conditions and are among the tumors with larger genomic instability. Here we discuss some intrinsic and extrinsic mechanisms of resistance of melanoma cells to both conventional and target therapies, such as autophagy, adaptation to endoplasmic reticulum stress, metabolic reprogramming, mechanisms of tumor repopulation and the role of extracellular vesicles in this later phenomenon. These biological processes are potentially targetable and thus provide a platform for research and discovery of new drugs for combination therapy to manage melanoma patient treatment.
Collapse
Affiliation(s)
- Renata de Freitas Saito
- Center for Translational Research in Oncology (LIM24), Dept. of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil
| | - Tharcísio Citrângulo Tortelli
- Center for Translational Research in Oncology (LIM24), Dept. of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil
| | - Mayara D'Auria Jacomassi
- Center for Translational Research in Oncology (LIM24), Dept. of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil
| | - Andréia Hanada Otake
- Center for Translational Research in Oncology (LIM24), Dept. of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil
| | - Roger Chammas
- Center for Translational Research in Oncology (LIM24), Dept. of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil.
| |
Collapse
|
17
|
Machado CML, Andrade LNS, Teixeira VR, Costa FF, Melo CM, dos Santos SN, Nonogaki S, Liu FT, Bernardes ES, Camargo AA, Chammas R. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFβ1-induced macrophages. Cancer Med 2014; 3:201-14. [PMID: 24421272 PMCID: PMC3987071 DOI: 10.1002/cam4.173] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2013] [Revised: 11/11/2013] [Accepted: 11/12/2013] [Indexed: 12/16/2022] Open
Abstract
In order to study the role of galectin-3 in tumor angiogenesis associated with tumor-associated macrophages (TAM) and tumor parenchyma, the galectin-3 expression was reconstituted in Tm1 melanoma cell line that lacks this protein. Galectin-3-expressing cells (Tm1G3) and mock-vector transfected cells (Tm1N3) were injected into wild-type (WT) and galectin-3 knockout (KO) C57Bl/6 mice. Tumors originated from Tm1G3 were larger in tumor volume with enlarged functional vessels, decreased necrotic areas, and increased vascular endothelial growth factor (VEGF) protein levels. Galectin-3-nonexpressing-cells injected into WT and KO showed increased levels of transforming growth factor beta 1 (TGFβ1) and, in WT animals this feature was also accompanied by increased VEGFR2 expression and its phosphorylation. In KO animals, tumors derived from galectin-3-expressing cells were infiltrated by CD68(+)-cells, whereas in tumors derived from galectin-3-nonexpressing-cells, CD68(+) cells failed to infiltrate tumors and accumulated in the periphery of the tumor mass. In vitro studies showed that Tm1G3 secreted more VEGF than Tm1N3 cells. In the latter case, TGFβ1 induced VEGF production. Basal secretion of VEGF was higher in WT-bone marrow-derived macrophages (BMDM) than in KO-BMDM. TGFβ1 induced secretion of VEGF only in WT-BMDM. Tm1G3-induced tumors had the Arginase I mRNA increased, which upregulated alternative macrophage (M2)/TAM induction. M2 stimuli, such as interleukin-4 (IL4) and TGFβ1, increased Arginase I protein levels and galectin-3 expression in WT- BMDM, but not in cells from KO mice. Hence, we report that galectin-3 disruption in tumor stroma and parenchyma decreases angiogenesis through interfering with the responses of macrophages to the interdependent VEGF and TGFβ1 signaling pathways.
Collapse
Affiliation(s)
- Camila Maria Longo Machado
- Laboratório de Oncologia Experimental-LIM24, Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil; Depto. de Radiologia e Oncologia, Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil; Laboratório de Investigação Médica Radioisotopos-LIM/43, Departamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Molognoni F, de Melo FHM, da Silva CT, Jasiulionis MG. Ras and Rac1, frequently mutated in melanomas, are activated by superoxide anion, modulate Dnmt1 level and are causally related to melanocyte malignant transformation. PLoS One 2013; 8:e81937. [PMID: 24358134 PMCID: PMC3864863 DOI: 10.1371/journal.pone.0081937] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Accepted: 10/25/2013] [Indexed: 12/22/2022] Open
Abstract
A melanocyte malignant transformation model was developed in our laboratory, in which different melanoma cell lines were obtained after submitting the non-tumorigenic melanocyte lineage melan-a to sequential cycles of anchorage impediment. Our group has already showed that increased superoxide level leads to global DNA hypermemethylation as well increased Dnmt1 expression few hours after melanocyte anchorage blockade. Here, we showed that Ras/Rac1/ERK signaling pathway is activated in melanocytes submitted to anchorage impediment, regulating superoxide levels, global DNA methylation, and Dnmt1 expression. Interestingly, Ras and Rac1 activation is not related to codon mutations, but instead regulated by superoxide. Moreover, the malignant transformation was drastically compromised when melan-a melanocytes were submitted to sequential cycles of anchorage blockage in the presence of a superoxide scavenger. This aberrant signaling pathway associated with a sustained stressful condition, which might be similar to conditions such as UV radiation and inflammation, seems to be an early step in malignant transformation and to contribute to an epigenetic reprogramming and the melanoma development.
Collapse
Affiliation(s)
- Fernanda Molognoni
- Departamento de Farmacologia, Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil
| | - Fabiana Henriques Machado de Melo
- Departamento de Farmacologia, Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil
| | - Camila Tainah da Silva
- Departamento de Farmacologia, Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil
| | | |
Collapse
|
19
|
da Costa PLN, Sirois P, Tannock IF, Chammas R. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett 2013; 345:27-38. [PMID: 24333733 DOI: 10.1016/j.canlet.2013.12.009] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Revised: 11/29/2013] [Accepted: 12/02/2013] [Indexed: 12/20/2022]
Abstract
Kinins are generated within inflammatory tissue microenvironments, where they exert diverse functions, including cell proliferation, leukocyte activation, cell migration, endothelial cell activation and nociception. These pleiotropic functions depend on signaling through two cross talking receptors, the constitutively expressed kinin receptor 2 (B2R) and the inducible kinin receptor 1 (B1R). We have reviewed evidence, which supports the concept that kinin receptors, especially kinin receptor 1, are promising targets for cancer therapy, since (1) many tumor cells express aberrantly high levels of these receptors; (2) some cancers produce kinins and use them as autocrine factors to stimulate their growth; (3) activation of kinin receptors leads to activation of macrophages, dendritic cells and other cells from the tumor microenvironment; (4) kinins have pro-angiogenic properties; (5) kinin receptors have been implicated in cancer migration, invasion and metastasis; and (6) selective antagonists for either B1R or B2R have shown anti-proliferative, anti-inflammatory, anti-angiogenic and anti-migratory properties. The multiple cross talks between kinin receptors and renin-angiotensin system (RAS) as well as its implications for targeting KKS or RAS for the treatment of malignancies are also discussed. It is expected that B1R antagonists would interfere less with housekeeping functions and therefore would be attractive compounds to treat selected types of cancer. Reliable clinical studies are needed to establish the translatability of these data to human settings and the usefulness of kinin receptor antagonists.
Collapse
Affiliation(s)
- Patrícia L N da Costa
- Laboratório de Oncologia Experimental, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil
| | - Pierre Sirois
- CHUL Research Center, Laval University, Quebec City, Canada
| | - Ian F Tannock
- Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
| | - Roger Chammas
- Laboratório de Oncologia Experimental, Faculdade de Medicina da Universidade de São Paulo and Instituto do Câncer do Estado de São Paulo, Brazil.
| |
Collapse
|
20
|
|
21
|
Comodo AN, Lacerda Bachi AL, Soares MF, Franco M, Castro Teixeira VDP. Galectin-3 expression favors metastasis in murine melanoma. ACTA ACUST UNITED AC 2013. [DOI: 10.4236/abb.2013.410a3007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
22
|
Yu T, Moh SH, Kim SB, Yang Y, Kim E, Lee YW, Cho CK, Kim KH, Yoo BC, Cho JY, Yoo HS. HangAmDan-B, an ethnomedicinal herbal mixture, suppresses inflammatory responses by inhibiting Syk/NF-κB and JNK/ATF-2 pathways. J Med Food 2012; 16:56-65. [PMID: 23256447 DOI: 10.1089/jmf.2012.2374] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
HangAmDan-B (HAD-B) is a powdered mixture of eight ethnopharmacologically characterized folk medicines that is prescribed for solid masses and cancers in Korea. In view of the finding that macrophage-mediated inflammation is a pathophysiologically important phenomenon, we investigated whether HAD-B modulates inflammatory responses and explored the associated molecular mechanisms. The immunomodulatory activity of HAD-B in toll-like receptor-activated macrophages induced by lipopolysaccharide (LPS) was assessed by measuring nitric oxide (NO) and prostaglandin E(2) (PGE(2)) levels. To identify the specific transcription factors (such as nuclear factor [NF]-κB and signaling enzymes) targeted by HAD-B, biochemical approaches, including kinase assays and immunoblot analysis, were additionally employed. HAD-B suppressed the production of PGE(2) and NO in LPS-activated macrophages in a dose-dependent manner. Furthermore, the extract ameliorated HCl/EtOH-induced gastritis symptoms. Moreover, HAD-B significantly inhibited LPS-induced mRNA expression of inducible NO synthase and cyclooxygenase (COX)-2. Interestingly, marked inhibition of NF-κB and activating transcription factor was observed in the presence of HAD-B. Data from direct kinase assays and immunoblot analysis showed that HAD-B suppresses activation of the upstream signaling cascade involving spleen tyrosine kinase, Src, p38, c-Jun N-terminal kinase, and transforming growth factor β-activated kinase 1. Finally, kaempferol, but not quercetin or resveratrol was identified as a bioactive compound in HAD-B. Therefore, our results suggest that HAD-B possesses anti-inflammatory activity that contributes to its anticancer property.
Collapse
Affiliation(s)
- Tao Yu
- Department of Genetic Engineering, Sungkyunkwan University, Suwon, Korea
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Apoptotic cells contribute to melanoma progression and this effect is partially mediated by the platelet-activating factor receptor. Mediators Inflamm 2012; 2012:610371. [PMID: 22577252 PMCID: PMC3346991 DOI: 10.1155/2012/610371] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2011] [Accepted: 02/01/2012] [Indexed: 12/31/2022] Open
Abstract
There is evidence that the platelet-activating factor receptor (PAFR) is involved in the clearance of apoptotic cells by macrophages, and that this is associated with anti-inflammatory phenotype. Our group has previously shown that coinjection of a large number of apoptotic cells can promote tumor growth from a subtumorigenic dose of melanoma cells. Here, we studied the involvement of the PAFR in the tumor growth promoting effect of apoptotic cells. A sub-tumorigenic dose of melanoma cells (Tm1) was coinjected with apoptotic Tm1 cells, subcutaneously in the flank of C57Bl/6 mice, and the volume was monitored for 30 days. Animals received the PAFR antagonists, WEB2170 or PCA4248 (5 mg/kg body weight) or vehicle, by peritumoral daily injection for 5 days. Results showed that PAFR antagonists significantly inhibited the tumor growth induced by the coinjection of a sub-tumorigenic dose of melanoma cells together with apoptotic cells. This was accompanied by inhibition of early neutrophil and macrophage infiltration. Addition of (platelet-activating factor) to this system has no significant effect. PAFR antagonists did not affect the promoting effect of carrageenan. We suggest that the recognition of apoptotic cells by phagocytes leads to activation of PAFR pathways, resulting in a microenvironment response favorable to melanoma growth.
Collapse
|
24
|
Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in melanoma. Mediators Inflamm 2012; 2012:175408. [PMID: 22570511 PMCID: PMC3337612 DOI: 10.1155/2012/175408] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2011] [Accepted: 02/02/2012] [Indexed: 12/26/2022] Open
Abstract
Melanoma cells express the platelet-activating factor receptor (PAFR) and, thus, respond to PAF, a bioactive lipid produced by both tumour cells and those in the tumour microenvironment such as macrophages. Here, we show that treatment of a human melanoma SKmel37 cell line with cisplatin led to increased expression of PAFR and its accumulation. In the presence of exogenous PAF, melanoma cells were significantly more resistant to cisplatin-induced cell death. Inhibition of PAFR-dependent signalling pathways by a PAFR antagonist (WEB2086) showed chemosensitisation of melanoma cells in vitro. Nude mice were inoculated with SKmel37 cells and treated with cisplatin and WEB2086. Animals treated with both agents showed significantly decreased tumour growth compared to the control group and groups treated with only one agent. PAFR accumulation and signalling are part of a prosurvival program of melanoma cells, therefore constituting a promising target for combination therapy for melanomas.
Collapse
|
25
|
Guimarães PB, Alvarenga ÉC, Siqueira PD, Paredes-Gamero EJ, Sabatini RA, Morais RL, Reis RI, Santos EL, Teixeira LG, Casarini DE, Martin RP, Shimuta SI, Carmona AK, Nakaie CR, Jasiulionis MG, Ferreira AT, Pesquero JL, Oliveira SM, Bader M, Costa-Neto CM, Pesquero JB. Angiotensin II Binding to Angiotensin I–Converting Enzyme Triggers Calcium Signaling. Hypertension 2011; 57:965-72. [PMID: 21422380 DOI: 10.1161/hypertensionaha.110.167171] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Angiotensin (Ang) I–converting enzyme (ACE) is involved in the control of blood pressure by catalyzing the conversion of Ang I into the vasoconstrictor Ang II and degrading the vasodilator peptide bradykinin. Human ACE also functions as a signal transduction molecule, and the binding of ACE substrates or its inhibitors initiates a series of events. In this study, we examined whether Ang II could bind to ACE generating calcium signaling. Chinese hamster ovary cells transfected with an ACE expression vector reveal that Ang II is able to bind with high affinity to ACE in the absence of the Ang II type 1 and type 2 receptors and to activate intracellular signaling pathways, such as inositol 1,4,5-trisphosphate and calcium. These effects could be blocked by the ACE inhibitor, lisinopril. Calcium mobilization was specific for Ang II, because other ACE substrates or products, namely Ang 1-7, bradykinin, bradykinin 1-5, and
N
-acetyl-seryl-aspartyl-lysyl-proline, did not trigger this signaling pathway. Moreover, in Tm5, a mouse melanoma cell line endogenously expressing ACE but not Ang II type 1 or type 2 receptors, Ang II increased intracellular calcium and reactive oxygen species. In conclusion, we describe for the first time that Ang II can interact with ACE and evoke calcium and other signaling molecules in cells expressing only ACE. These findings uncover a new mechanism of Ang II action and have implications for the understanding of the renin-Ang system.
Collapse
Affiliation(s)
- Paola B. Guimarães
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Érika C. Alvarenga
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Paula D. Siqueira
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Edgar J. Paredes-Gamero
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Regiane A. Sabatini
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Rafael L.T. Morais
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Rosana I. Reis
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Edson L. Santos
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Luis G.D. Teixeira
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Dulce E. Casarini
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Renan P. Martin
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Suma I. Shimuta
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Adriana K. Carmona
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Clovis R. Nakaie
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Miriam G. Jasiulionis
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Alice T. Ferreira
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Jorge L. Pesquero
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Suzana M. Oliveira
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Michael Bader
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - Claudio M. Costa-Neto
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| | - João B. Pesquero
- From the Departamento de Biofísica (P.B.G., É.C.A., P.D.S., E.J.P.-G., R.A.S., R.L.T.M., L.G.D.T., R.P.M., S.I.S., A.K.C., C.R.N., A.T.F., S.M.O., J.B.P.), Departamento de Medicina (D.E.C.), and Departamento de Farmacologia (M.G.J.), Universidade Federal de São Paulo, São Paulo, Brazil; Departamento de Bioquímica e Imunologia (R.I.R., C.M.C.-N.), Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil; Faculdade de Ciências Biológicas e Ambientais (E.L.S.), Universidade
| |
Collapse
|
26
|
de Oliveira SI, Andrade LNS, Onuchic AC, Nonogaki S, Fernandes PD, Pinheiro MC, Rohde CBS, Chammas R, Jancar S. Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy. BMC Cancer 2010; 10:200. [PMID: 20465821 PMCID: PMC2881890 DOI: 10.1186/1471-2407-10-200] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2009] [Accepted: 05/13/2010] [Indexed: 01/07/2023] Open
Abstract
Background Phagocytosis of apoptotic cells by macrophages induces a suppressor phenotype. Previous data from our group suggested that this occurs via Platelet-activating factor receptor (PAF-R)-mediated pathways. In the present study, we investigated the impact of apoptotic cell inoculation or induction by a chemotherapeutic agent (dacarbazine, DTIC) on tumour growth, microenvironmental parameters and survival, and the effect of treatment with a PAF-R antagonist (WEB2170). These studies were performed in murine tumours: Ehrlich Ascitis Tumour (EAT) and B16F10 melanoma. Methods Tumour growth was assessed by direct counting of EAT cells in the ascitis or by measuring the volume of the solid tumour. Parameters of the tumour microenvironment, such as the frequency of cells expressing cyclo-oxygenase-2 (COX-2), caspase-3 and galectin-3, and microvascular density, were determined by immunohistochemistry. Levels of vascular endothelium growth factor (VEGF) and prostaglandin E2 (PGE2) were determined by ELISA, and levels of nitric oxide (NO) by Griess reaction. PAF-R expression was analysed by immunohistochemistry and flow cytometry. Results Inoculation of apoptotic cells before EAT implantation stimulated tumour growth. This effect was reversed by in vivo pre-treatment with WEB2170. This treatment also reduced tumour growth and modified the microenvironment by reducing PGE2, VEGF and NO production. In B16F10 melanoma, WEB2170 alone or in association with DTIC significantly reduced tumour volume. Survival of the tumour-bearing mice was not affected by WEB2170 treatment but was significantly improved by the combination of DTIC with WEB2170. Tumour microenvironment elements were among the targets of the combination therapy since the relative frequency of COX-2 and galectin-3 positive cells and the microvascular density within the tumour mass were significantly reduced by treatment with WEB2170 or DTIC alone or in combination. Antibodies to PAF-R stained the cells from inside the tumour, but not the tumour cells grown in vitro. At the tissue level, a few cells (probably macrophages) stained positively with antibodies to PAF-R. Conclusions We suggest that PAF-R-dependent pathways are activated during experimental tumour growth, modifying the microenvironment and the phenotype of the tumour macrophages in such a way as to favour tumour growth. Combination therapy with a PAF-R antagonist and a chemotherapeutic drug may represent a new and promising strategy for the treatment of some tumours.
Collapse
Affiliation(s)
- Soraya I de Oliveira
- Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma. Neoplasia 2010; 12:11-9. [PMID: 20072649 DOI: 10.1593/neo.91004] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2009] [Revised: 09/20/2009] [Accepted: 09/22/2009] [Indexed: 12/28/2022] Open
Abstract
Aneuploidy and chromosomal instability (CIN) are hallmarks of most solid tumors. These alterations may result from inaccurate chromosomal segregation during mitosis, which can occur through several mechanisms including defective telomere metabolism, centrosome amplification, dysfunctional centromeres, and/or defective spindle checkpoint control. In this work, we used an in vitro murine melanoma model that uses a cellular adhesion blockade as a transforming factor to characterize telomeric and centromeric alterations that accompany melanocyte transformation. To study the timing of the occurrence of telomere shortening in this transformation model, we analyzed the profile of telomere length by quantitative fluorescent in situ hybridization and found that telomere length significantly decreased as additional rounds of cell adhesion blockages were performed. Together with it, an increase in telomere-free ends and complex karyotypic aberrations were also found, which include Robertsonian fusions in 100% of metaphases of the metastatic melanoma cells. These findings are in agreement with the idea that telomere length abnormalities seem to be one of the earliest genetic alterations acquired in the multistep process of malignant transformation and that telomere abnormalities result in telomere aggregation, breakage-bridge-fusion cycles, and CIN. Another remarkable feature of this model is the abundance of centromeric instability manifested as centromere fragments and centromeric fusions. Taken together, our results illustrate for this melanoma model CIN with a structural signature of centromere breakage and telomeric loss.
Collapse
|
28
|
Bachi ALL, Kim FJK, Nonogaki S, Carneiro CRW, Lopes JD, Jasiulionis MG, Correa M. Leukotriene B4 Creates a Favorable Microenvironment for Murine Melanoma Growth. Mol Cancer Res 2009; 7:1417-24. [DOI: 10.1158/1541-7786.mcr-09-0038] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia 2008; 9:1111-21. [PMID: 18084618 DOI: 10.1593/neo.07712] [Citation(s) in RCA: 111] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2007] [Revised: 10/02/2007] [Accepted: 10/03/2007] [Indexed: 12/30/2022] Open
Abstract
Both oxidative/nitrosative stress and alterations in DNA methylation are observed during carcinogenesis of different tumor types, but no clear correlation between these events has been demonstrated until now. Melanoma cell lines were previously established after submitting the nontumorigenicmelanocyte lineage, melan-a, to cycles of anchorage blockade. In this work, increased intracellular oxidative species and nitric oxide levels, as well as alterations in the DNA methylation, were observed after melan-a detachment, which were also associated with a decrease in intracellular homocysteine (Hcy), an element in the methionine (universal methyl donor) cycle. This alteration was accompanied by increase in glutathione (GSH) levels and methylated DNA content. Furthermore, a significant increase in dnmt1 and 3b expression was identified along melan-a anchorage blockade. L(G)-Nitro-L-arginine methyl esther (L-NAME), known as a nitric oxide synthase (NOS) inhibitor, and N-acetyl-L-cysteine (NAC) prevented the increase in global DNA methylation, as well as the increase in dnmt1 and 3b expression, observed during melan-a detachment. Interestingly, both L-NAME and NAC did not inhibit nitric oxide (NO) production in these cells, but abrogated superoxide anion production during anchorage blockade. In conclusion, oxidative stress observed during melanocyte anchorage blockade seems to modulate DNA methylation levels and may directly contribute to the acquisition of an anoikis-resistant phenotype through an epigenetic mechanism.
Collapse
|
30
|
Mendes PFP, Xander P, Novaes e Brito RR, Mortara RA, Jasiulionis MG, Lopes JD. A cell surface 230 kDa protein from murine melanoma involved with tumor malignancy. Cancer Lett 2008; 262:276-85. [PMID: 18226856 DOI: 10.1016/j.canlet.2007.12.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2007] [Revised: 12/04/2007] [Accepted: 12/05/2007] [Indexed: 12/13/2022]
Abstract
Because melanoma incidence has increased at a dramatic rate, it is relevant to identify novel melanoma antigens for diagnosis and develop monoclonal antibodies recognizing such molecules. Some monoclonal antibodies (mAbs), raised against murine melanoma, identify molecules correlated with carcinogenesis. Herein, we describe a murine melanoma-associated 230 kDa molecule, expressed only in tumorigenic cell lines. Moreover, its expression is higher in more metastatic than less metastatic cells. G12F2 mAb, produced against this antigen, inhibited in vitro proliferation of both murine and human melanoma cells and enhanced in vitro complement activity. It also affected in vivo tumor growth and lung metastases formation. This 230kDa molecule represents an important target for experimental melanoma studies and may become a potential diagnostic marker for malignancy as well as a useful tool for immunotherapeutic approaches.
Collapse
Affiliation(s)
- Priscila Fraga Penteado Mendes
- Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo, São Paulo 04023-901, Brazil
| | | | | | | | | | | |
Collapse
|
31
|
Bollos RH, Nakamura MU, Lapchick VBV, Bevilacqua EMAF, Correa M, Daher S, Ishigai MMS, Jasiulionis MG. Metastatic melanoma positively influences pregnancy outcome in a mouse model: could a deadly tumor support embryo life? Clin Exp Metastasis 2007; 25:65-73. [DOI: 10.1007/s10585-007-9102-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2007] [Accepted: 09/21/2007] [Indexed: 12/31/2022]
|
32
|
Jasiulionis MG, Luchessi AD, Moreira AG, Souza PPC, Suenaga APM, Correa M, Costa CAS, Curi R, Costa-Neto CM. Inhibition of eukaryotic translation initiation factor 5A (eIF5A) hypusination impairs melanoma growth. Cell Biochem Funct 2007; 25:109-14. [PMID: 16850525 DOI: 10.1002/cbf.1351] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The eukaryotic translation initiation factor 5A (eIF5A) undergoes a specific post-translational modification called hypusination. This modification is required for the functionality of this protein. The compound N1-guanyl-1,7-diaminoheptane (GC7) is a potent and selective inhibitor of deoxyhypusine synthase, which catalyses the first step of eIF5A hypusination process. In the present study, the effects of GC7 on cell death were investigated using two cell lines: melan-a murine melanocytes and Tm5 murine melanoma. In vitro treatment with GC7 increased by 3-fold the number of cells presenting DNA fragmentation in Tm5 cells. Exposure to GC7 also decreased viability to both cell lines. This study also describes, for the first time, the in vivo antitumour effect of GC7, as indicated by impaired melanoma growth in C57BL/6 mice.
Collapse
Affiliation(s)
- Miriam G Jasiulionis
- Department of Micro-Immuno-Parasitology, Federal University of São Paulo, 04023-062, São Paulo, Brazil
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Oba-Shinjo SM, Correa M, Ricca TI, Molognoni F, Pinhal MA, Neves IA, Marie SK, Sampaio LO, Nader HB, Chammas R, Jasiulionis MG. Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 2006; 8:231-41. [PMID: 16611417 PMCID: PMC1578519 DOI: 10.1593/neo.05781] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Exclude experimental models of malignant transformation employ chemical and physical carcinogens or genetic manipulations to study tumor progression. In this work, different melanoma cell lines were established after submitting a nontumorigenic melanocyte lineage (melan-a) to sequential cycles of forced anchorage impediment. The great majority of these cells underwent anoikis when maintained in suspension. After one deadhesion cycle, phenotypic alterations were noticeable in the few surviving cells, which became more numerous and showed progressive alterations after each adhesion impediment step. No significant differences in cell surface expression of integrins were detected, but a clear electrophoretic migration shift, compatible with an altered glycosylation pattern, was observed for beta1 chain in transformed cell lines. In parallel, a progressive enrichment of tri- and tetra-antennary N-glycans was apparent, suggesting increased N-acetylglucosaminyltransferase V activity. Alterations both in proteoglycan glycosylation pattern and core protein expression were detected during the transformation process. In conclusion, this model corroborates the role of adhesion state as a promoting agent in transformation process and demonstrates that cell adhesion disturbances may act as carcinogenic stimuli, at least for a nontumorigenic immortalized melanocyte lineage. These findings have intriguing implications for in vivo carcinogenesis, suggesting that anchorage independence may precede, and contribute to, neoplastic conversion.
Collapse
MESH Headings
- Animals
- Anoikis
- Cell Adhesion
- Cell Line, Transformed/transplantation
- Cell Lineage
- Cell Transformation, Neoplastic
- Cells, Cultured/cytology
- Chondroitin Sulfate Proteoglycans/biosynthesis
- Chondroitin Sulfate Proteoglycans/genetics
- Culture Media, Serum-Free
- Decorin
- Extracellular Matrix Proteins/biosynthesis
- Extracellular Matrix Proteins/genetics
- Female
- Fibronectins
- Flow Cytometry
- Gene Expression Regulation, Neoplastic
- Glucuronidase/biosynthesis
- Glucuronidase/genetics
- Glycosaminoglycans/analysis
- Heparan Sulfate Proteoglycans/biosynthesis
- Heparan Sulfate Proteoglycans/genetics
- Integrins/metabolism
- Laminin
- Lectins, C-Type/biosynthesis
- Lectins, C-Type/genetics
- Melanocytes/cytology
- Melanocytes/metabolism
- Melanocytes/transplantation
- Melanoma, Experimental/genetics
- Melanoma, Experimental/metabolism
- Melanoma, Experimental/pathology
- Mice
- Mice, Inbred C57BL
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Phenotype
- Proteoglycans/biosynthesis
- Proteoglycans/genetics
- RNA, Neoplasm/biosynthesis
- RNA, Neoplasm/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Versicans
Collapse
Affiliation(s)
- Sueli M Oba-Shinjo
- Laboratório de Biologia Molecular, Departamento de Neurologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
de Souza GA, Godoy LMF, Teixeira VR, Otake AH, Sabino A, Rosa JC, Dinarte AR, Pinheiro DG, Silva WA, Eberlin MN, Chammas R, Greene LJ. Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics 2006; 6:1460-70. [PMID: 16429458 DOI: 10.1002/pmic.200500243] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Using 2-DE of total cell protein extracts, we compared soluble proteins from murine melanoma lines Tm1 and Tm5 with proteins from the nontumoral cell melan-a from which they were derived. Seventy-one of the 452 spots (average) detected with CBB were differentially accumulated, i.e., increased or decreased twofold. Forty-four spots were identified by PMF/MALDI-TOF, 15 with increased and 29 with decreased protein levels. SAGE showed that 17/34 (50%) of the differentially accumulated proteins, pI range 4-7, presented similar differences at the mRNA level. Major reductions in protein were observed in tumor cells of proteins that degrade reactive oxygen species (ROS). Decreases of > or = twofold in GST, superoxide dismutase, aldehyde dehydrogenase, thioredoxin, peroxiredoxin 2, and peroxiredoxin 6 protein were observed. SAGE indicated the reduction of other proteins involved in ROS degradation. As expected, the accumulation of exogenous peroxides was significantly higher in the tumor cells while the levels of glutathionylation were two times lower in the tumor cells compared to melan-a. The differential accumulation of proteins involved in oncogene/tumor suppressor pathways was observed. Melanoma cells can favor survival pathways activated by ROS by inhibiting p53 pathways and activation of Ras and c-myc pathways.
Collapse
Affiliation(s)
- Gustavo A de Souza
- Centro de Terapia Celular, Centro Regional de Hemoterapia de Ribeirão Preto, Centro de Pesquisa, Inovação e Difusão - FAPESP, Brasil
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|